The purpose of this study is to measure patient satisfaction with telecommunication visits during adjuvant chemotherapy as opposed to the more typical in-person visit. Telecommunication is defined as communication over a distance using technology. For the purposes of this study, patients will engage in video conferencing with their physician as well having in-person clinic visits. This research is being done because telecommunication visits are being considered as an alternative for in-patient visits; however, the data is currently limited. This clinical study will help investigators to evaluate feasibility and satisfaction of the visits done by telecommunication.
Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital
- Biopsy-proven stage II or III carcinoma of the colon or rectum.
- No prior treatment with either 5-FU or oxaliplatin within the last 6 months.
- No other chemotherapy within 4 weeks of protocol treatment initiation.
- Additional eligibility in protocol
- Acute treatment for an infection or other serious medical illness within 14 days prior to study entry.
- Major surgery or radiation therapy within 3 weeks prior to study treatment initiation.
- Known hypersensitivity to oxaliplatin , 5-FU or capecitibine.
- Patients who have any severe or uncontrolled medical conditions or other conditions that could affect their participation in this study, including: unstable angina, serious uncontrolled cardiac arrhythmia, active acute or uncontrolled infectious disorder, or myocardial infarction ≤ 6 months prior to study entry.
- Additional ineligibility in protocol